Rick Panicucci 2

Rick Panicucci, Ph.D.

Chief Development Officer

Rick Panicucci, Ph.D., is Co-founder of MaveriX Oncology and has been involved with the company since incorporation in 2016.  Rick currently holds the position of Senior Vice President of CMC at BridgeBio and has held a number of senior leadership roles in drug and business development in the pharmaceutical industry over the past 25 years. Rick was formerly Vice President of Pharmaceutical Development at STA Pharmaceutical Co., Ltd. (A WuXi AppTec Company). At STA Rick was responsible for providing scientific leadership in the areas of Developability, Formulation Development and GMP Manufacturing. Prior to STA Rick was Global Head of Chemical and Pharmaceutical Profiling (CPP) at Novartis from 2004 to 2015. Responsibilities included analytics, solid state chemistry, formulation development and drug delivery of the entire Novartis early R&D portfolio. He worked closely with Novartis BD&L and Venture Fund on many external deals. Rick currently holds the position of Adjunct Professor at Massachusetts College of Pharmacy. Other Previous positions include the Director of Formulation Development at Vertex Pharmaceuticals, Director of Research and Development at Symbollon Pharmaceuticals and Senior Scientist at Biogen. He started his career at Bausch & Lomb in the pre-formulation lab and was promoted to Manager of Process Development. His education includes two post-doctoral fellowships at University of California at Santa Barbara and the Ontario Cancer Institute. He received his Ph.D. in Physical Organic Chemistry from the University of Toronto.